{"id":"mmf-cyclosporine-steroids","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (bacterial, viral, fungal)"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Gingival hyperplasia"}]},"_chembl":{"chemblId":"CHEMBL406352","moleculeType":"Small molecule","molecularWeight":"1202.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MMF (mycophenolate mofetil) inhibits inosine monophosphate dehydrogenase to selectively suppress T and B cell proliferation. Cyclosporine blocks calcineurin signaling to prevent T-cell activation and cytokine production. Corticosteroids provide broad anti-inflammatory effects by suppressing multiple immune cell functions. Together, these agents provide complementary immunosuppression for transplant rejection prevention.","oneSentence":"This triple immunosuppressive regimen suppresses T-cell activation and proliferation through multiple pathways to prevent organ rejection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:21:47.574Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in transplant recipients"},{"name":"Autoimmune and inflammatory conditions requiring immunosuppression"}]},"trialDetails":[{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT01282073","phase":"PHASE3","title":"Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy","status":"COMPLETED","sponsor":"Kyungpook National University Hospital","startDate":"2011-03","conditions":"Glomerulonephritis, Membranous","enrollment":43},{"nctId":"NCT01002339","phase":"PHASE4","title":"Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation","status":"TERMINATED","sponsor":"Armando Torres Ramírez","startDate":"2010-02","conditions":"Diabetes Mellitus, Adult-Onset","enrollment":134},{"nctId":"NCT04989491","phase":"PHASE4","title":"Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2021-12-01","conditions":"Epstein-Barr Virus Infections","enrollment":120},{"nctId":"NCT02416388","phase":"PHASE2, PHASE3","title":"Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2015-01","conditions":"Acute Myeloid Leukemia (AML)","enrollment":3100},{"nctId":"NCT02867800","phase":"PHASE1","title":"Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease","status":"COMPLETED","sponsor":"Monica Bhatia","startDate":"2016-07","conditions":"Sickle Cell Disease, Graft Versus Host Disease","enrollment":24},{"nctId":"NCT02426502","phase":"NA","title":"Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of British Columbia","startDate":"2016-04","conditions":"End-Stage Renal Disease","enrollment":76},{"nctId":"NCT00574496","phase":"PHASE2","title":"Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-11-13","conditions":"Lymphoma","enrollment":25},{"nctId":"NCT05293509","phase":"PHASE2","title":"Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-02","conditions":"Stem Cell Transplantation","enrollment":""},{"nctId":"NCT02936505","phase":"NA","title":"Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2016-10-12","conditions":"Lung Transplantation, Allografts","enrollment":249},{"nctId":"NCT05553496","phase":"PHASE2, PHASE3","title":"Assessment of Rituximab Therapeutic Response Versus Conventional Treatment","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-09-25","conditions":"Pharmacological Action","enrollment":40},{"nctId":"NCT00579527","phase":"PHASE1, PHASE2","title":"Phase I/II Thymus Transplantation With Immunosuppression #950","status":"COMPLETED","sponsor":"Sumitomo Pharma Switzerland GmbH","startDate":"2005-12-19","conditions":"DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly","enrollment":14},{"nctId":"NCT04424862","phase":"PHASE4","title":"Multitarget Therapy for Idiopathic Membranous Nephropathy","status":"COMPLETED","sponsor":"Beijing Friendship Hospital","startDate":"2020-06-09","conditions":"Efficacy","enrollment":82},{"nctId":"NCT00136903","phase":"PHASE2","title":"Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2005-04-27","conditions":"Graft Vs Host Disease","enrollment":32},{"nctId":"NCT00075829","phase":"PHASE3","title":"Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2003-12","conditions":"Multiple Myeloma","enrollment":710},{"nctId":"NCT00630253","phase":"PHASE1, PHASE2","title":"Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2000-02-17","conditions":"Fanconi Anemia","enrollment":31},{"nctId":"NCT04101578","phase":"","title":"Clinical Prognosis and Progression of Myasthenia Gravis Patients","status":"UNKNOWN","sponsor":"Da, Yuwei, M.D.","startDate":"2017-02-08","conditions":"Myasthenia Gravis","enrollment":2000},{"nctId":"NCT01921218","phase":"PHASE3","title":"Belatacept Therapy for the Failing Renal Allograft","status":"COMPLETED","sponsor":"Andrew B Adams","startDate":"2013-08","conditions":"Failing Renal Allograft","enrollment":13},{"nctId":"NCT01062555","phase":"PHASE1, PHASE2","title":"Calcineurin Inhibitor Sparing After Kidney Transplantation","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2006-10-01","conditions":"CNI Side Effects","enrollment":527},{"nctId":"NCT00377962","phase":"PHASE4","title":"Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-12","conditions":"Disorder Related to Cardiac Transplantation","enrollment":282},{"nctId":"NCT00154193","phase":"PHASE4","title":"Nordic Study in Cardiac and Lung Transplantation: Outcome in Relation to Cyclosporine Microemulsion C2 Levels","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-06","conditions":"Heart and Lung Transplant","enrollment":190},{"nctId":"NCT00185692","phase":"PHASE2","title":"Allogeneic Transplantation From Related Haploidentical Donors","status":"COMPLETED","sponsor":"Stanford University","startDate":"2000-08","conditions":"Blood Cancer, Leukemia, Graft Versus Host Disease","enrollment":16},{"nctId":"NCT00568633","phase":"PHASE3","title":"Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML","status":"TERMINATED","sponsor":"Stanford University","startDate":"2007-08","conditions":"Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia (AML)","enrollment":58},{"nctId":"NCT02042690","phase":"PHASE3","title":"Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients","status":"COMPLETED","sponsor":"Peking University","startDate":"2014-07","conditions":"Acute Lymphoblastic Leukemia","enrollment":131},{"nctId":"NCT03791827","phase":"","title":"Multicenter Registry of Pediatric Lupus Nephritis in China","status":"UNKNOWN","sponsor":"Xiqiang Dang","startDate":"2018-12-01","conditions":"Lupus Nephritis, Children, Steroid","enrollment":1200},{"nctId":"NCT03170323","phase":"PHASE4","title":"Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2018-07-01","conditions":"Idiopathic Membranous Nephropathy","enrollment":128},{"nctId":"NCT00135694","phase":"PHASE2","title":"Gradual Withdrawal of Immune System Suppressing Drugs in Patients Receiving a Liver Transplant","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-10","conditions":"Hepatitis C, Hepatitis C, Chronic, Nonimmune Nonviral Causes of Liver Failure","enrollment":275},{"nctId":"NCT01950819","phase":"PHASE4","title":"Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-03","conditions":"End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD), Hemodialysis","enrollment":2037},{"nctId":"NCT01093586","phase":"PHASE2","title":"Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2007-09","conditions":"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7)","enrollment":14},{"nctId":"NCT00482053","phase":"PHASE2","title":"Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT","status":"TERMINATED","sponsor":"Stanford University","startDate":"2006-10","conditions":"Lymphoma, B-cell, Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":3},{"nctId":"NCT00481832","phase":"PHASE2","title":"Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Stanford University","startDate":"2007-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":50},{"nctId":"NCT00354172","phase":"PHASE2","title":"Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2006-02","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":16},{"nctId":"NCT00290628","phase":"NA","title":"Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"1999-10","conditions":"Chronic Myeloproliferative Disorders, Diamond-blackfan Anemia, Fanconi Anemia","enrollment":43},{"nctId":"NCT00186628","phase":"PHASE2","title":"Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD","status":"COMPLETED","sponsor":"Stanford University","startDate":"2005-06","conditions":"Leukemia, Mast-Cell, Mantle-cell Lymphoma","enrollment":36},{"nctId":"NCT00899847","phase":"PHASE2","title":"Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-05","conditions":"Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma","enrollment":9},{"nctId":"NCT00281879","phase":"PHASE2","title":"Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":200},{"nctId":"NCT02904772","phase":"PHASE2","title":"Alipogene Tiparvovec for the Treatment of LPLD Patients","status":"WITHDRAWN","sponsor":"UniQure Biopharma B.V.","startDate":"2016-10","conditions":"LPL Deficiency","enrollment":""},{"nctId":"NCT01410448","phase":"PHASE3","title":"Everolimus in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-11","conditions":"Kidney Transplantation","enrollment":383},{"nctId":"NCT00157014","phase":"PHASE3","title":"Canadian Cardiology de Novo Study: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-05-10","conditions":"Heart Diseases, Heart Transplantation","enrollment":111},{"nctId":"NCT01114529","phase":"PHASE3","title":"Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-08-09","conditions":"Kidney Transplantation","enrollment":828},{"nctId":"NCT00075478","phase":"PHASE3","title":"Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2003-10","conditions":"Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Aggressive Non-Hodgkin Lymphoma","enrollment":87},{"nctId":"NCT01797315","phase":"PHASE4","title":"Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol","status":"TERMINATED","sponsor":"University Hospital of Berlin","startDate":"2007-03","conditions":"Renal Transplant Patients at High-risk for Skin Cancer","enrollment":40},{"nctId":"NCT00425308","phase":"PHASE3","title":"Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-10","conditions":"Renal Transplantation","enrollment":30},{"nctId":"NCT00154206","phase":"PHASE4","title":"Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Cyclosporine Microemulsion and Steroids in Pediatric de Novo Renal Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-09","conditions":"Kidney Transplantation","enrollment":15},{"nctId":"NCT00239798","phase":"PHASE2","title":"Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-11","conditions":"Renal Transplantation","enrollment":255},{"nctId":"NCT02058875","phase":"PHASE4","title":"Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring","status":"WITHDRAWN","sponsor":"University of Saskatchewan","startDate":"2014-02","conditions":"Cardiovascular Disease, Cardiovascular Outcomes, Kidney Transplant Recipients","enrollment":""},{"nctId":"NCT00132691","phase":"PHASE4","title":"Multicenter Uveitis Steroid Treatment (MUST) Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2005-09","conditions":"Uveitis","enrollment":255},{"nctId":"NCT00048165","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"1999-08","conditions":"Heart Transplantation","enrollment":434},{"nctId":"NCT02686619","phase":"PHASE3","title":"Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-11","conditions":"Renal Transplantation","enrollment":237},{"nctId":"NCT02005562","phase":"PHASE3","title":"OPERA Study: A Study of Two Dosing Regimens of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-05","conditions":"Kidney Transplantation","enrollment":252},{"nctId":"NCT01067300","phase":"PHASE3","title":"A Study Comparing Single Versus Double Umbilical Cord Blood Transplantation in the Young With Acute Leukemia Remission","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2010-02","conditions":"Leukemia","enrollment":198},{"nctId":"NCT00309218","phase":"PHASE3","title":"Steroid Withdrawal in Pediatric Renal Transplant Recipients Under Cyclosporine (CyA) and Mycophenolate Mofetil (MMF)","status":"COMPLETED","sponsor":"Klinik für Kinder- und Jugendmedizin","startDate":"1999-03","conditions":"Kidney Diseases","enrollment":42},{"nctId":"NCT00298324","phase":"PHASE3","title":"Myfortic - Treatment for Extensive cGvHD","status":"TERMINATED","sponsor":"European Society for Blood and Marrow Transplantation","startDate":"2006-09","conditions":"Graft vs Host Disease","enrollment":34},{"nctId":"NCT01017029","phase":"PHASE4","title":"Everolimus in de Novo Heart Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-09","conditions":"Cardiac Transplantation","enrollment":182},{"nctId":"NCT02091414","phase":"PHASE3","title":"A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-08","conditions":"Heart Transplantation","enrollment":36},{"nctId":"NCT01817322","phase":"PHASE4","title":"Kidney Graft Function Under the Immunosuppression Strategies","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2011-06","conditions":"Chronic Renal Disease","enrollment":140},{"nctId":"NCT00972660","phase":"PHASE2","title":"Safety and Efficacy Study of Allogenic Mesenchymal Stem Cells to Treat Extensive Chronic Graft Versus Host Disease","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2009-09","conditions":"Graft Versus Host Disease","enrollment":52},{"nctId":"NCT00634920","phase":"PHASE4","title":"Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-03","conditions":"Renal Function","enrollment":204},{"nctId":"NCT00355862","phase":"PHASE3","title":"Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"University of Regensburg","startDate":"2006-01","conditions":"Hepatocellular Carcinoma","enrollment":525},{"nctId":"NCT01596062","phase":"PHASE2","title":"Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Renal Transplantation","enrollment":16},{"nctId":"NCT00956293","phase":"PHASE4","title":"Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-07","conditions":"Renal Transplantation","enrollment":207},{"nctId":"NCT01079143","phase":"PHASE3","title":"Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus Based Versus CNI Based) in de Novo Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-09","conditions":"Renal Interstitial Fibrosis","enrollment":194},{"nctId":"NCT01706471","phase":"PHASE4","title":"Safety and Efficacy of the Early Introduction of Everolimus (Certican®) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-06","conditions":"Planned Kidney Transplantation","enrollment":60},{"nctId":"NCT00182559","phase":"PHASE4","title":"The Vienna Prograf and Endothelial Progenitor Cell Study","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2004-04","conditions":"End Stage Renal Disease","enrollment":148},{"nctId":"NCT00008307","phase":"PHASE2","title":"Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders","status":"UNKNOWN","sponsor":"Herbert Irving Comprehensive Cancer Center","startDate":"1998-04","conditions":"Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm","enrollment":52},{"nctId":"NCT00334672","phase":"PHASE3","title":"Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis","status":"UNKNOWN","sponsor":"Children's Cancer and Leukaemia Group","startDate":"2006-03","conditions":"Nonneoplastic Condition","enrollment":288},{"nctId":"NCT00371826","phase":"PHASE4","title":"SOCRATES: Steroid or Cyclosporine Removal After Transplantation Using Everolimus","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-03","conditions":"Renal Transplanted Recipients","enrollment":126},{"nctId":"NCT01609673","phase":"NA","title":"Study of Everolimus in de Novo Renal Transplant Recipients","status":"TERMINATED","sponsor":"Helady Pinheiro, MD, PhD","startDate":"2013-03","conditions":"End Stage Renal Failure With Renal Transplant","enrollment":1},{"nctId":"NCT00452361","phase":"PHASE4","title":"Study Evaluating of Calcineurin Inhibitors Versus Sirolimus in Renal Allograft Recipient","status":"TERMINATED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-04","conditions":"Kidney Transplantation","enrollment":31},{"nctId":"NCT00214279","phase":"NA","title":"MMF Monotherapy and Immune Regulation in Kidney Transplant Recipients: Part 1 Steroid Withdrawal","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2002-05","conditions":"Renal Transplantation","enrollment":32},{"nctId":"NCT00187941","phase":"EARLY_PHASE1","title":"MPA PK Monitoring Strategy With MMF/FK Based Immunosuppression","status":"COMPLETED","sponsor":"University of Florida","startDate":"2005-08","conditions":"Transplantation, Renal, Immunosuppression","enrollment":22},{"nctId":"NCT01613963","phase":"","title":"Causes of Visual Loss in Retinal Disease","status":"UNKNOWN","sponsor":"Royal Surrey County Hospital NHS Foundation Trust","startDate":"2012-05","conditions":"Uveitis, Scleritis","enrollment":2000},{"nctId":"NCT00135811","phase":"PHASE3","title":"Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2004-11","conditions":"Glomerulosclerosis, Focal","enrollment":207},{"nctId":"NCT00254709","phase":"PHASE4","title":"Study Evaluating Two Different Sirolimus-based Immunosuppressive Regimens in Elderly Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2002-10","conditions":"Kidney Failure, Graft Rejection, Aged","enrollment":66},{"nctId":"NCT00260208","phase":"PHASE4","title":"Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-01","conditions":"Liver Transplant, Hepatitis C","enrollment":361},{"nctId":"NCT00238992","phase":"PHASE3","title":"Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2002-12","conditions":"Kidney de Novo Transplant","enrollment":144},{"nctId":"NCT00284921","phase":"PHASE3","title":"MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-04","conditions":"De Novo Kidney Transplant","enrollment":60},{"nctId":"NCT00891306","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects","status":"COMPLETED","sponsor":"Amsterdam Molecular Therapeutics","startDate":"2009-02","conditions":"Familial Lipoprotein Lipase Deficiency","enrollment":5},{"nctId":"NCT01429844","phase":"PHASE3","title":"Tacrolimus Versus Cyclosporine for Immunosuppression After Lung Transplantation","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2001-01","conditions":"Bronchiolitis Obliterans, Immunosuppression","enrollment":274},{"nctId":"NCT01023542","phase":"PHASE2, PHASE3","title":"CNI-free \"Bottom\"-up Immunosuppression in Patients Undergoing Liver Transplantation","status":"UNKNOWN","sponsor":"University of Regensburg","startDate":"2011-06","conditions":"Renal Impairment, Liver Transplantation, Everolimus","enrollment":45},{"nctId":"NCT00251004","phase":"PHASE3","title":"Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-10","conditions":"Kidney Transplantation, Graft Rejection","enrollment":833},{"nctId":"NCT00413920","phase":"PHASE3","title":"Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without Steroids, in Adult Renal Transplant Recipients","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-04","conditions":"Renal Transplantation","enrollment":222},{"nctId":"NCT00267189","phase":"PHASE3","title":"RESCUE Study - Everolimus in Liver Transplantation Recipients With Renal Insufficiency","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-11","conditions":"Liver Transplantation","enrollment":145},{"nctId":"NCT00419926","phase":"PHASE4","title":"Evaluation of the Therapeutic Benefit of an Initial Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Regimen in Renal Transplant Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-12","conditions":"Kidney Transplantation","enrollment":313},{"nctId":"NCT00308425","phase":"PHASE3","title":"Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) Plus Valsartan in Patients With Kidney Transplants (MYTHOS","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-10","conditions":"De Novo Renal Transplantation","enrollment":119},{"nctId":"NCT00239031","phase":"PHASE3","title":"Study of Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Reduced-dose Cyclosporine Microemulsion (CsA-ME) Compared to EC-MPS Plus Standard Dose CsA-ME in Eldery de Novo Renal Transplant Recipients Treated With Basiliximab and Short-term Steroids","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-03","conditions":"Denovo Renal Transplantation","enrollment":117},{"nctId":"NCT00101738","phase":"PHASE3","title":"Freedom Study: Myfortic in Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2003-03","conditions":"Kidney Transplantation","enrollment":342},{"nctId":"NCT00239057","phase":"PHASE3","title":"Study of Enteric-coated Mycophenolate Sodium Maintenance Therapy in Patients With Renal Transplant Receiving Cyclosporine Microemulsion and Steroids,","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-05","conditions":"Maintenance Renal Transplantation","enrollment":23},{"nctId":"NCT00238901","phase":"PHASE3","title":"Efficacy and Safety of Basiliximab in Hepatitis C Virus Positive Patients Undergoing Liver Transplantation","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-12","conditions":"Liver Transplant","enrollment":194},{"nctId":"NCT00228020","phase":"PHASE3","title":"Study of Safety and Efficacy of a Basiliximab, Mycophenolate Mofetil, Cyclosporine Microemulsion and Prednisone Combination Treatment Regimen in Pediatric Renal Allograft Recipients","status":"COMPLETED","sponsor":"Novartis","startDate":"2001-05","conditions":"Pediatric Kidney Transplantation","enrollment":212},{"nctId":"NCT00903188","phase":"PHASE4","title":"Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation","status":"UNKNOWN","sponsor":"University Hospital, Antwerp","startDate":"2008-10","conditions":"Renal Transplantation","enrollment":152},{"nctId":"NCT00359658","phase":"NA","title":"Withdrawal of Steroids, Cyclosporine A Dose Reduction and Switch to Mycophenolatmofetile After Heart Transplantation","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2004-11","conditions":"Heart Transplantation","enrollment":40},{"nctId":"NCT00695344","phase":"PHASE4","title":"Study to Evaluate Effect of Everolimus in Progression of Graft Vascular Illness on Patients With Heart Transplant","status":"UNKNOWN","sponsor":"Fundacion Investigacion y Desarrollo","startDate":"2006-01","conditions":"Cardiac Transplant","enrollment":52},{"nctId":"NCT00812123","phase":"PHASE4","title":"Calcineurin Free Immunosuppression in Renal Transplant Recipients","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2001-01","conditions":"Kidney Transplantation, Chronic Kidney Disease","enrollment":127},{"nctId":"NCT00706680","phase":"PHASE4","title":"Thymoglobulin in Calcineurin Inhibitor and Steroid Minimization Protocol","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2008-02","conditions":"Diabetes, Graft Rejection","enrollment":30},{"nctId":"NCT00138970","phase":"PHASE4","title":"Calcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk","status":"COMPLETED","sponsor":"University of Oslo School of Pharmacy","startDate":"2002-01","conditions":"Renal Transplant Recipients","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MMF, cyclosporine, steroids","genericName":"MMF, cyclosporine, steroids","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple immunosuppressive regimen suppresses T-cell activation and proliferation through multiple pathways to prevent organ rejection. Used for Prevention of organ rejection in transplant recipients, Autoimmune and inflammatory conditions requiring immunosuppression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}